{"id":749996,"date":"2023-04-21T08:08:01","date_gmt":"2023-04-21T12:08:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/"},"modified":"2023-04-21T08:08:01","modified_gmt":"2023-04-21T12:08:01","slug":"cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/","title":{"rendered":"Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules"},"content":{"rendered":"

<\/p>\n

Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules<\/b><\/p>\n

GAINESVILLE, Fla.–(BUSINESS WIRE<\/a>)–Cyclo Therapeutics, Inc.<\/a> (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed a private placement of its securities priced at-the-market under Nasdaq rules, with a group of accredited investors that included several directors of the Company and members of management. Investors in the private placement purchased 1,562,883 shares of common and were issued warrants to purchase 1,562,883 shares of common. The purchase price for one share of common stock and a warrant to purchase one share of common stock was $0.84. The warrants have an exercise price of $0.71 and have a term of seven years. The gross proceeds of the private placement were approximately $1.3 million.<\/p>\n

\nCyclo Therapeutics intends to use the net proceeds from the financing for working capital and general corporate purposes, including in support of its Trappsol\u00ae<\/sup> Cyclo\u2122 development programs.<\/p>\n

\nThe securities described above were offered by Cyclo Therapeutics in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the \u201cAct\u201d) and\/or Regulation D promulgated thereunder, and such securities have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. The securities were issued by the Company directly to investors with whom the Company had a pre-existing relationship, without the services of a placement agent or other intermediary.<\/p>\n

\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.<\/p>\n

About Cyclo Therapeutics<\/i><\/b><\/p>\n

\nCyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease. The Company\u2019s Trappsol\u00ae<\/sup> Cyclo\u2122, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov<\/a>NCT02939547<\/a>, NCT02912793<\/a>, NCT03893071<\/a> and NCT04860960<\/a>). The Company is conducting a Phase 2b clinical trial using Trappsol\u00ae<\/sup> Cyclo\u2122 intravenously in early Alzheimer\u2019s disease (NCT05607615<\/a>) based on encouraging data from an Expanded Access program for Alzheimer\u2019s disease (NCT03624842<\/a>). Additional indications for the active ingredient in Trappsol\u00ae<\/sup> Cyclo\u2122 are in development. For additional information, visit the Company\u2019s website: www.cyclotherapeutics.com<\/a>.<\/p>\n

Safe Harbor Statement<\/i><\/b><\/p>\n

\nThis press release contains \u201cforward-looking statements\u201d about the company\u2019s current expectations about future results, performance, prospects and opportunities, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering. Statements that are not historical facts, such as \u201canticipates,\u201d \u201cbelieves\u201d and \u201cexpects\u201d or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company\u2019s future performance include the company\u2019s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company\u2019s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company\u2019s filings with the Securities and Exchange Commission, including, but not limited to, the company\u2019s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230421005104\/en\/<\/a><\/span><\/p>\n

\nJTC Team, LLC
\n
Jenene Thomas
\n
(833) 475-8247
\n
CYTH@jtcir.com<\/a><\/p>\n

KEYWORDS:<\/b> Florida United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Other Health Health Genetics Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed a private placement of its securities priced at-the-market under Nasdaq rules, with a group of accredited investors that included several directors of the Company and members of management. Investors in the private placement purchased 1,562,883 shares of common and were issued warrants to purchase 1,562,883 shares of common. The purchase price for one share of common stock and a warrant to purchase one share of common stock … <\/p>\n

Continue reading “Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-749996","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed a private placement of its securities priced at-the-market under Nasdaq rules, with a group of accredited investors that included several directors of the Company and members of management. Investors in the private placement purchased 1,562,883 shares of common and were issued warrants to purchase 1,562,883 shares of common. The purchase price for one share of common stock and a warrant to purchase one share of common stock … Continue reading "Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-21T12:08:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230421005104r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules\",\"datePublished\":\"2023-04-21T12:08:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\\\/\"},\"wordCount\":746,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230421005104r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\\\/\",\"name\":\"Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230421005104r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-04-21T12:08:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230421005104r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230421005104r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/","og_locale":"en_US","og_type":"article","og_title":"Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Market Newsdesk","og_description":"Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed a private placement of its securities priced at-the-market under Nasdaq rules, with a group of accredited investors that included several directors of the Company and members of management. Investors in the private placement purchased 1,562,883 shares of common and were issued warrants to purchase 1,562,883 shares of common. The purchase price for one share of common stock and a warrant to purchase one share of common stock … Continue reading \"Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-21T12:08:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230421005104r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules","datePublished":"2023-04-21T12:08:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/"},"wordCount":746,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230421005104r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/","name":"Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230421005104r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-04-21T12:08:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230421005104r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230421005104r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-closing-of-1-3-million-private-placement-priced-at-the-market-under-nasdaq-rules\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=749996"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749996\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=749996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=749996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=749996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}